首页|间歇性高通量血液透析联合左卡尼汀静脉注射应用于维持性血液透析患者的效果

间歇性高通量血液透析联合左卡尼汀静脉注射应用于维持性血液透析患者的效果

扫码查看
目的:探讨间歇性高通量血液透析(high-flux hemodialysis,HFHD)联合左卡尼汀静脉注射在维持性血液透析患者中的应用效果。方法:选取 2021 年 3 月—2023 年 5 月在漳州市第二医院接受治疗的 80 例维持性血液透析患者,根据随机数表法分为接受间歇性HFHD的对照组(n=40)和接受间歇性HFHD联合左卡尼汀静脉注射治疗的试验组(n=40)。比较两组患者的铁代谢水平、微炎症状态、生活质量、不良反应发生率。结果:治疗 3 个月后,两组转铁蛋白饱和度、铁蛋白均高于治疗前,且试验组高于对照组,差异有统计学意义(P<0。05);治疗 3 个月后,两组白细胞介素-6、C反应蛋白均低于治疗前,且试验组低于对照组,差异有统计学意义(P<0。05);治疗 3 个月后,两组生存质量测量量表中环境、心理、生理、社会关系评分均高于治疗前,且试验组高于对照组,差异有统计学意义(P<0。05);治疗期间,两组不良反应总发生率比较,差异无统计学意义(P>0。05)。结论:间歇性HFHD联合左卡尼汀静脉注射可调节维持性血液透析患者的铁代谢水平,改善微炎症状态,有利于生活质量的提升,具有一定的安全性。
Effects of Intermittent High-flux Hemodialysis Combined with Levocarnitine Intravenous Injection in Maintenance Hemodialysis Patients
Objective:To explore the effect of intermittent high-flux hemodialysis(HFHD)combined with Levocarnitine intravenous dialysis in maintenance hemodialysis patients.Method:A total of 80 patients with maintenance hemodialysis who received treatment in Zhangzhou Second Hospital from March 2021 to May 2023 were selected and they were divided into the control group receiving intermittent HFHD(n=40)and the experimental group receiving intermittent HFHD combined with Levocarnitine intravenous injection(n=40)according to the random number table method.Iron metabolism level,microinflammatory status,quality of life and incidence of adverse reactions were compared between the two groups.Result:After 3 months of treatment,the transferrin saturation and ferritin level in the two groups were higher than before treatment,and the indexes in the experimental group were higher than those in the control group,the differences were statistically significant(P<0.05).After 3 months of treatment,the levels of interleukin-6 and C-reactive protein in the two groups were lower than those before treatment,and the indexes in the experimental group were lower than those in the control group,the differences were statistically significant(P<0.05).After 3 months of treatment,the scores of quality of life measurement scale such as environmental,psychological,physiological,social relations in the two groups were higher than those before treatment,and the indexes in the experimental group were higher than those in the control group,the differences were statistically significant(P<0.05).During treatment,the total incidence of adverse reactions in the two group were compared,but the difference was not statistically significant(P>0.05).Conclusion:Intravenous injection of intermittent HFHD combined with Levocarnitine can regulate the iron metabolism level in maintenance hemodialysis patients,improve the microinflammatory state,and contribute to the improvement of quality of life,with certain safety.

Intermittent high-flux hemodialysisLevocarnitineMaintenance hemodialysisIron metabolism

郑叶明

展开 >

漳州市第二医院 福建 漳州 363000

间歇性高通量血液透析 左卡尼汀 维持性血液透析 铁代谢

2024

中外医学研究
中国医院管理杂志社

中外医学研究

影响因子:1.149
ISSN:1674-6805
年,卷(期):2024.22(26)